 eFitnessNow [1] |
FDA extended time to review saxagliptin for treatment of diabetes [3] [2]
Endocrine Today, NJ The FDA has extended the date of the Prescription Drug User Fee Act from April 30, 2009 to July 30, 2009, stating that additional time is needed to complete the review of saxagliptin for the treatment of type 2 diabetes [3]. … FDA extends timeline to approve diabetes [4] drug of Bristol-Myers … diabetes [5]_drug_Onglyza.html&cid=1339678364&ei=Hgf1SbukGqKcggOr9_yGDA&usg=AFQjCNEAsmMGKXwdDF-1ASODvUHyFyKw5A”>FDA wants more time to review diabetes drug Onglyza AstraZeneca: FDA Extends Timeline For Onglyza NDA To July 30 [6] |